Reata and Kyowa Kirin are burying bardoxolone methyl after new phase 3 data laid bare the dwindling—if not non-existent—potential of the kidney disease treatment. The two companies said that while the ...
Biogen Inc. has announced plans to acquire Reata Pharmaceuticals, Inc. for $7.3 billion, validating the potential of Skyclarys. Skyclarys, the sole FDA-approved treatment for Friedreich's ataxia, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results